ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
about
Ser/Thr protein kinase Bβ-NADPH oxidase 2 signaling in thromboinflammation.In vitro evidence of complement activation in patients with sickle cell disease.Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.Myeloperoxidase Negatively Regulates Neutrophil-Endothelial Cell Interactions by Impairing αMβ2 Integrin Function in Sterile Inflammation.The Akt pathway in oncology therapy and beyond (Review)
P2860
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@en
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@nl
type
label
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@en
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@nl
prefLabel
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@en
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@nl
P2093
P2860
P1433
P1476
ARQ 092, an orally-available, ...... ctions in sickle cell disease.
@en
P2093
Alan Tseng
Andrew Barazia
Giovanni Abbadessa
Jaehyung Cho
Kyungho Kim
Seock-Won Youn
Victor R Gordeuk
P2860
P304
P356
10.3324/HAEMATOL.2016.151159
P577
2016-10-06T00:00:00Z